Indomethacin Reduces Glomerular and Tubular Damage Markers but Not Renal Inflammation in Chronic Kidney Disease Patients: A Post-Hoc Analysis by de Borst, Martin H. et al.
Indomethacin Reduces Glomerular and Tubular Damage
Markers but Not Renal Inflammation in Chronic Kidney
Disease Patients: A Post-Hoc Analysis
Martin H. de Borst
1*, Ferdau L. Nauta
1, Liffert Vogt
2, Gozewijn D. Laverman
1, Ron T. Gansevoort
1,
Gerjan Navis
1
1Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen and University of Groningen, Groningen, the Netherlands, 2Department
of Nephrology, Academic Medical Center, Amsterdam, the Netherlands
Abstract
Under specific conditions non-steroidal anti-inflammatory drugs (NSAIDs) may be used to lower therapy-resistant
proteinuria. The potentially beneficial anti-proteinuric, tubulo-protective, and anti-inflammatory effects of NSAIDs may be
offset by an increased risk of (renal) side effects. We investigated the effect of indomethacin on urinary markers of
glomerular and tubular damage and renal inflammation. We performed a post-hoc analysis of a prospective open-label
crossover study in chronic kidney disease patients (n=12) with mild renal function impairment and stable residual
proteinuria of 4.764.1 g/d. After a wash-out period of six wks without any RAAS blocking agents or other therapy to lower
proteinuria (untreated proteinuria (UP)), patients subsequently received indomethacin 75 mg BID for 4 wks (NSAID). Healthy
subjects (n=10) screened for kidney donation served as controls. Urine and plasma levels of total IgG, IgG4, KIM-1, beta-2-
microglobulin, H-FABP, MCP-1 and NGAL were determined using ELISA. Following NSAID treatment, 24 h -urinary excretion
of glomerular and proximal tubular damage markers was reduced in comparison with the period without anti-proteinuric
treatment (total IgG: UP 131[38–513] vs NSAID 38[17–218] mg/24 h, p,0.01; IgG4: 50[16–68] vs 10[1–38] mg/24 h, p,0.001;
beta-2-microglobulin: 200[55–404] vs 50[28–110] ug/24 h, p=0.03; KIM-1: 9[5–14] vs 5[2–9] ug/24 h, p=0.01). Fractional
excretions of these damage markers were also reduced by NSAID. The distal tubular marker H-FABP showed a trend to
reduction following NSAID treatment. Surprisingly, NSAID treatment did not reduce urinary excretion of the inflammation
markers MCP-1 and NGAL, but did reduce plasma MCP-1 levels, resulting in an increased fractional MCP-1 excretion. In
conclusion, the anti-proteinuric effect of indomethacin is associated with reduced urinary excretion of glomerular and
tubular damage markers, but not with reduced excretion of renal inflammation markers. Future studies should address
whether the short term glomerulo- and tubulo-protective effects as observed outweigh the possible side-effects of NSAID
treatment on the long term.
Citation: de Borst MH, Nauta FL, Vogt L, Laverman GD, Gansevoort RT, et al. (2012) Indomethacin Reduces Glomerular and Tubular Damage Markers but Not
Renal Inflammation in Chronic Kidney Disease Patients: A Post-Hoc Analysis. PLoS ONE 7(5): e37957. doi:10.1371/journal.pone.0037957
Editor: Dominique Guerrot, Rouen University Hospital, France
Received January 1, 2012; Accepted April 30, 2012; Published May 25, 2012
Copyright:  2012 de Borst et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The original study that served as the source of the current post-hoc analysis was supported by Merck & Company (grant MSGP 9661). Dr. De Borst is
supported by personal development grants from the Dutch Kidney foundation (KJPB.08.07; http://www.nierstichting.nl) and the University Medical Center
Groningen (Mandema stipend). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Part of the original study was supported by Merck & Company (grant MSGP 9661). This does not alter the authors’ adherence to all the
PLoS ONE policies on sharing data and materials.
* E-mail: m.h.de.borst@umcg.nl
Introduction
Reduction of proteinuria is a major therapy target to achieve
long-term renoprotection in chronic kidney disease. To this end,
blockade of the renin-angiotensin-aldosterone system (RAAS)
ideally combined with a diuretic or dietary sodium restriction
[1] is the cornerstone of current renoprotective therapy in chronic
kidney disease [2,3]. Nevertheless, chronic kidney disease (CKD)
progression persists in a considerable proportion of patients.
Particularly in patients with high residual proteinuria despite
RAAS blockade, there may be a place for alternative modes of
antiproteinuric intervention, such as non-steroidal anti-inflamma-
tory drugs (NSAIDs) [4].
Before the era of RAAS inhibitors, NSAIDs were well known
for a distinct antiproteinuric effect. Their use in nephrotic
syndrome was supported by retrospective data suggesting that
NSAIDs may retard progression of renal function loss [5,6],
although not all data are uniform [7].
Most renoprotective effects of NSAIDs are considered to be
related to their effect on prostaglandin synthesis [8]. Prostaglandin
inhibition reduces effective renal plasma flow (ERPF) and
glomerular filtration rate (GFR), presumably resulting in a
reduction of intraglomerular pressure, in turn leading to a
reduction of proteinuria [9]. Moreover, through inhibition of
prostaglandin synthesis, NSAIDs reduce inflammation, a determi-
nant of renal and cardiovascular outcome in CKD [10,11]. Recent
elegant studies implicated a central role for increased cyclooxy-
genase-2 (COX-2) expression in podocytes in the etiology of
glomerular injury which could be reversed by COX-2 inhibition
[12,13]. Beside these beneficial effects, however, NSAIDs also
have side-effects in several organ systems including the gastro-
intestinal tract (e.g. peptic ulcers) and central nervous system side-
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damage have been reported [14,15]. Since the presence of
tubulointerstitial damage is a determinant of response to
renoprotective therapy [11], this may negatively impact prognosis
for CKD patients.
To further investigate the glomerular, tubular and anti-
inflammatory effects of NSAIDs in CKD, we measured a panel
of urinary renal damage markers representing different parts of the
nephron in patients with overt proteinuria, before and after
treatment with indomethacin. As a secondary aim we investigated
whether pretreatment biomarker levels were associated with the
anti-proteinuric response.
Materials and Methods
Ethics Statement
The study was approved by the medical ethics committee of the
University of Groningen, and all participants provided written
informed consent. All clinical investigations have been conducted
according to the principles expressed in the Declaration of
Helsinki.
Patients
This study is performed as a post-hoc analysis of a prospective
open-label crossover study [16]. This study was performed in
Caucasian patients (n=16) who fulfilled the following inclusion
criteria after a 6 week washout period without RAAS intervention:
proteinuria .2 g/day, diastolic blood pressure ,90 mmHg,
creatinine clearance .30 mL/min and age 18–70 years. Blood
and urine samples were available for 12 out of 16 patients due to
biobank exhaustion: seven patients with non-diabetic nephropathy
(membranous glomerulopathy (n=2), primary focal segmental
glomerular sclerosis (2), IgA nephropathy (2) and hypertensive
nephropathy (1)), and five with (type 2) diabetic nephropathy.
Diagnoses were established by kidney biopsy for all patients. The
characteristics of these patients were similar to the original study
population. Healthy subjects who were screened for kidney
donation in our center were included as controls (n=10).
Study Protocol
The detailed study protocol was published previously [16].
During an initial washout period, blood pressure was titrated with
hydrochlorothiazide 12.5 mg QD combined with amlodipine or
doxazosine if necessary; this regimen remained unchanged during
the actual study. Following the washout period without anti-
proteinuric treatment, urine and blood samples were collected.
Subsequently patients were treated with indomethacin 75 mg BID
(retard formula; IndocidH Merck & Co., Inc., Whitehouse Station,
NJ, USA) for four weeks. At the end of this period a second set of
urine and blood samples were collected.
Clinical Measurements
At each visit, after an overnight fast, blood was sampled, 24-h
urine was collected and blood pressure was measured by an
automatic device (DinamapH, GE Healthcare, Waukesha, WI,
USA). Twentyfour-hour urine was checked for collection errors
using the equation previously formulated by Ix et al [17]. The
mean arterial blood pressure (MAP) was calculated as 2/36
diastolic blood pressure +1/36systolic blood pressure. The mean
value of four readings after 15 min was used for analysis. Urinary
protein was determined with the pyrogallol red-molybdate
method. Serum creatinine, albumin and lipids were determined
using an automated multi-analyzer (MEGAH, Merck, Darmstadt,
Germany).
Measurement of Damage Markers
Aliquots from 24 h -urine were stored at 280uC until damage
marker analysis. After thawing, all urine samples were vortexed
and subsequently centrifuged (14.000 rpm). The supernatant was
used for measurements. Samples were diluted to obtain optimal
concentration for measurement. All urinary biomarkers were
determined in one run. As glomerular damage markers we
measured total IgG and IgG4, as markers of proximal tubular
damage kidney injury molecule-1 (KIM-1) and beta-2-microglo-
bulin (B2M), as markers of distal tubular damage heart-fatty acid
binding protein (H-FABP), and as markers of inflammation
neutrophil gelatinase associated lipocalin (NGAL), monocyte
chemotactic protein-1 (MCP-1), as documented previously [18].
Urinary concentrations of total IgG, IgG4, NGAL, KIM-1, and
H-FABP were measured by enzyme-linked immunosorbent assay.
For KIM-1, B2M and NGAL, antibodies were obtained from
R&D Systems (Minneapolis, MN, intra-assay CV 7.4%, 9.7% and
6.8%, respectively). H-FABP and total IgG, IgG-4 antibodies were
obtained from Hytest (Turku, Finland, intra-assay CV 9.3%,
13.3% and 14.0%, respectively). All samples were measured in
duplicate.
The 24-h excretion of renal damage markers was calculated by
multiplying the urinary biomarker concentration with the total
24 h urine volume. Fractional excretion of renal damage markers
was calculated as:
FEmarker(%)~100x(½urinemarker 
 ½ plasmacreatinine )=(½plasmamarker 
 ½ urinecreatinine )
Statistical Analyses
Data are expressed as median (interquartile range). Differences
between healthy controls and CKD patients without anti-
proteinuric treatment were analyzed by Mann Whitney non-
parametric test. Differences between the study periods without
anti-proteinuric treatment versus NSAID treatment, respectively,
were analyzed by Wilcoxon paired non-parametric test. Associa-
tions between urinary biomarker excretion and proteinuria were
studied using linear regression with proteinuria as an independent
variable, and the individual renal damage markers as dependent
variables. For these analyses, urinary biomarker excretions were
logarithmically transformed. We also determined whether the
change in biomarker excretion between the study period without
anti-proteinuric treatment and NSAID (delta biomarker) was
related to the anti-proteinuric response (delta proteinuria).
Furthermore similar analysis were performed for the association
between biomarker excretion during the period without anti-
proteinuric therapy (i.e. before anti-proteinuric intervention) and
the anti-proteinuric response, to evaluate which biomarker(s)
would be able to predict the anti-proteinuric response. For all
analyses, a two-sided p,0.05 was considered statistically signifi-
cant.
All calculations and analyses were performed using SPSS 18.0
for Windows (SPSS Inc., Chicago, Illinois, USA).
Results
Baseline characteristics are given in Table 1. In CKD patients,
proteinuria was reduced by NSAID treatment with a median of
51% (IQR 33–73%) compared with the study period without anti-
proteinuric treatment (‘‘untreated UP’’; Figure 1A). CKD patients
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controls. After four weeks of treatment with indomethacin,
creatinine clearance showed a non-significant trend to further
reduction (Figure 1B).
In parallel with proteinuria, 24-h urinary excretions of the
glomerular damage markers total IgG and IgG4 were strongly
increased in CKD patients as compared to healthy controls. Anti-
proteinuric treatment with indomethacin reduced urinary total
IgG and IgG4 excretion (Table 2). Plasma levels of total IgG and
IgG4 were not affected by NSAID treatment (Table S1); therefore
fractional excretion of these markers decreased significantly during
treatment (Table 3). The glomerular charge selectivity index,
calculated as the ratio of the fractional excretions of total IgG/
IgG4, increased with NSAID treatment (untreated proteinuria:
6.98[1.24–16.8] vs NSAID 9.96[2.02–30.92], p,0.05).
The two proximal tubular markers KIM-1 and B2M were
elevated in CKD patients during the study period without anti-
proteinuric treatment, as compared to healthy controls, and
reduced by NSAID treatment (Table 2). Fractional excretion of
these markers was also significantly reduced by NSAID treatment
(Table 3). Urinary excretion of the distal tubular marker H-FABP
was elevated in untreated proteinuric patients when compared to
healthy controls, and NSAID treatment resulted in a non-
significant trend to reduced H-FABP excretion (Table 2) and a
significant decline in plasma H-FABP levels (Table S1). Conse-
quently the fractional excretion of H-FABP remained unchanged.
We subsequently investigated whether the anti-inflammatory
drug indomethacin would affect renal inflammation, as reflected
by urinary MCP-1 and NGAL excretion. Surprisingly, indometh-
acin did not reduce the 24 h -urinary excretions of MCP-1 or
NGAL, both of which were higher in CKD patients than in
healthy subjects (Table 2). In plasma, however, MCP-1 levels but
not NGAL levels were reduced by indomethacin (Table S1). As a
result, the fractional excretion of MCP1 increased (Table 3).
The relationship between urinary renal damage marker
excretions and proteinuria was further investigated by regression
analysis. Univariate analysis indicated that urinary excretions of
total IgG (standardized beta.691, p,.001), IgG4 (standardized
beta.642, p,.001), KIM-1 (standardized beta.662, p,.001), B2M
(standardized beta.466, p,.05), and H-FABP (standardized
beta.454, p,.05) were significantly associated with proteinuria.
As expected, delta urinary total IgG excretion (with vs without
antiproteinuric treatment, standardized beta.739, p,.01) and
delta urinary IgG4 excretion (standardized beta.721, p,.01) were
significantly associated with the anti-proteinuric response.
Finally we studied whether renal damage marker excretion
during the period without anti-proteinuric treatment (i.e. before
anti-proteinuric therapy) would be associated with the anti-
proteinuric response to indomethacin. Interestingly, urinary
excretion of KIM-1 (standardized beta 20.673, p,0.05) and
MCP-1 (standardized beta 20.854, p,0.001) before anti-protein-
uric treatment was inversely associated with the anti-proteinuric
response. After adjustment for age and genderonly the association
between MCP-1 and the anti-proteinuric response remained
significant (standardized beta 20.662, p,0.01). A scatter plot
illustrating the relationship between pre-treatment MCP-1 levels
and the anti-proteinuric response is presented in Figure 2.
Discussion
RAAS blockade combined with volume restriction is the
therapy of choice for most CKD patients, but the anti-proteinuric
response to this regimen is often incomplete [19]. Therefore it is
crucial to identify interventions that can serve as (adjunct) anti-
proteinuric therapies. The main finding of the current study is that
the anti-proteinuric effect of the NSAID indomethacin is
accompanied by reduced urinary 24 h -excretion of glomerular
and tubular damage markers. The 24 h -urinary excretion of
inflammation markers, on the other hand, was not affected by
NSAID treatment, and the fractional excretion of MCP-1 was
even increased.
The reduced urinary excretion of glomerular damage markers
total IgG and IgG4 is in line with the known anti-proteinuric effect
of indomethacin, and may be related to prostaglandin inhibition
affecting renal hemodynamics (i.e. vasoconstriction of the afferent
arterioles). Furthermore, both 24 h -urinary excretion and
fractional excretion of the proximal tubular damage markers were
reduced following treatment with an NSAID, and the distal
Table 1. Baseline characteristics of proteinuric CKD patients and healthy controls.
Healthy controls CKD untreated CKD+NSAID
n1 0 1 2 1 2
Age (years) 57 (41–68) 56 (42–67) 56 (42–67)
Male sex (%) 70 69 69
Diabetes mellitus (n) 0 5* 5
Systolic blood pressure (mmHg)
$ 119 (105–151) 142 (125–179)* 148 (130–165)
Diastolic blood pressure (mmHg)
$ 70 (55–84) 81 (72–95)* 79 (74–85)
BMI (kg/m
2) 27 (23–29) 28 (23–38) 28 (25–34)
Body weight (kg) 87 (74–97) 89 (76–101) 88 (77–105)
Creatinine clearance (ml/min) 113 (59–187) 79 (30–155)* 70 (28–140)
Proteinuria (g/24 h) 0.0 (0.0–0.2) 3.3 (0.6–14.6)** 1.2 (0.7–2.5)
##
UNaV (mmol/24 h) 219 (148–266) 213 (127–253) 173 (109–210)
#
FE sodium (%) 0.9 (0.6–1.3) 1.5 (1.2–3.5)** 1.5 (1.1–2.9)
BMI, body mass index; UNaV, urinary sodium excretion; FE, fractional excretion.
*p,0.05, **p,0.01 CKD untreated vs healthy controls.
#p,0.05,
## p,0.01 CKD NSAID vs CKD untreated.
$Antihypertensive use remained stable during the study protocol.
doi:10.1371/journal.pone.0037957.t001
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suggests that NSAIDs may have protective effects, rather than
toxic effects, on the tubular epithelium. Tubulotoxic effects may be
seen in rare cases, but in our study on average signs of reduction of
tubular damage are observed, probably secondary to the anti-
proteinuric effect of NSAID treatment. This is in concert with
previously observed tubulo-protective effects of RAAS-related
anti-proteinuric therapy in both clinical cohorts [20] as well as
preclinical studies, where also an association with protection
against structural renal damage was observed [21,22]. In addition,
direct protective (e.g. anti-apoptotic) effects as implicated by in
vitro studies [15] may play a role. NSAID treatment did not
significantly affect the distal tubular marker H-FABP, although a
trend to reduction was observed. Much less is known about the
effects of proteinuria on distal as compared to proximal tubular
cells, although the distal tubule is considered less sensitive to the
Figure 1. Proteinuria and creatinine clearance. A. Proteinuria was strongly increased in proteinuric CKD patients as compared to matched
healthy controls. NSAID treatment significantly reduced proteinuria. B. Creatinine clearance was significantly lower in untreated CKD patients,
whereas NSAID treatment did not significantly affect creatinine clearance. Horizontal lines indicate medians.
doi:10.1371/journal.pone.0037957.g001
Table 2. 24-h urinary excretion of renal damage markers in healthy controls, CKD patients after a period with no anti-proteinuric
treatment (untreated UP), and after NSAID treatment.
Damage marker Healthy controls Untreated UP P vs healthy NSAID P vs untreated UP
Total IgG (mg/24 h) 3.9 (2.9–5.6) 130.9 (37.8–513.4) ,0.001 38.1 (17.0–218.4) ,0.01
IgG4 (mg/24 h) 0.0 (0.0–0.1) 50.3 (16.4–68.3) ,0.001 10.2 (1.2–38.0) ,0.001
KIM-1 (mg/24 h) 2.3 (1.6–4.9) 8.9 (5.2–13.9) 0.004 4.6 (2.0–7.8) 0.01
B2M (mg/24 h) 56.3 (34.8–75.6) 199.5 (54.9–404.2) 0.03 47.8 (27.6–109.6) 0.03
H-FABP (mg/24 h) 0.0 (0.0–0.2) 28.4 (8.7–11.9) ,0.001 9.1 (1.2–89.9) 0.11
MCP-1 (mg/24 h) 0.8 (0.4–1.1) 1.8 (0.9–2.6) 0.01 1.8 (1.1–2.3) 0.88
NGAL (mg/24 h) 23.0 (15.1–29.4) 37.2 (29.2–89.9) 0.001 35.2 (26.8–89.9) 0.37
doi:10.1371/journal.pone.0037957.t002
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associated with albuminuria in diabetic subjects; moreover, H-
FABP was the only damage marker from the investigated marker
set that was significantly associated with eGFR after adjustment
for albuminuria [18]. Future studies should address the relevance
of H-FABP modulation by antiproteinuric therapy.
Surprisingly, NSAID treatment had no effect on the 24 h-
urinary excretion of inflammation markers MCP-1 or NGAL. In
contrast, fractional excretion of MCP-1 even increased following
NSAID treatment. This was unexpected given the anti-inflamma-
tory properties of this drug. On the other hand, the dissociation of
renoprotective effects from anti-inflammatory effects of NSAIDs is
in line with preclinical studies [15,23]. Furthermore, we recently
found that in a cohort of CKD patients receiving an angiotensin
receptor blocker in addition to an angiotensin converting enzyme
inhibitor, urinary excretion of proximal tubular markers was
reduced, but inflammatory markers did not change (data submitted).
Our finding that the extent of pre-treatment renal inflammation is
independently associated with the anti-proteinuric response is also
in line with preclinical studies [11]. This finding may have two
important implications. First, these data suggest that the
renoprotective potential of NSAIDs may be limited by the absence
of intra-renal anti-inflammatory effects (in spite of systemic anti-
inflammatory effects as reflected by lower plasma MCP-1 and
B2M levels). Second, these data suggest that the antiproteinuric,
and potentially also the renoprotective effect of NSAIDs is limited
to disease states with less intra-renal inflammation, for instance
excluding the use of these drugs in immune-mediated renal
disease.
Treatment with indomethacin induced a trend towards
decreased creatinine clearance in our study, and although this
reduction was relatively small, our study lacks power to exclude
an effect on renal function. Previous studies demonstrated an
anti-proteinuric response in the presence of a significant decline
of GFR following NSAID treatment [24,25]. The limited
decline in creatinine clearance in our study may also be
explained by the sodium replete state of our population.
Although dietary salt restriction is part of current best available
renoprotective therapy, in clinical practice it is notoriously
difficult to implement a persistent reduction in dietary salt
intake, and in fact in most published studies, the salt intake of
CKD patients is similar to that in the general population [26]
[26]. In line, several landmark randomized controlled trials
published over the last years have also not been performed
against the background of dietary sodium restriction. In the
setting of NSAID treatment, however, sodium restriction may
increase the risk of a fall in GFR [4]. Of note, the
antiproteinuric effect of NSAIDs has also been described to
be blunted by sodium repletion at least in severely nephrotic
patients [27]. The current anti-proteinuric efficacy of NSAID
treatment despite high sodium intake is therefore remarkable,
suggesting an optimal balance between efficacy and safety of
NSAIDs under liberal sodium intake. Our findings also suggest
that NSAID treatment increased charge selectivity, which is
known to be reduced in nephrotic-range proteinuria [28].
NSAIDs are nowadays rarely considered for anti-proteinuric
therapy in CKD. This is for the large part explained by the
availability of RAAS blockers with a more favorable potential,
whereas NSAIDs may have tubulotoxic effects. Also, the
reduction of creatinine clearance observed in up to 20% of
patients treated with NSAIDs [29,30], although reversible and
presumably reflecting a beneficial renal hemodynamic effect
(lowering of intraglomerular pressure), has raised concern
against using these drugs in patients with CKD. In our study,
none of the 24 h-excretions of renal damage markers increased
following NSAID treatment as compared to the period without
anti-proteinuric treatment. The decrease in creatinine clearance
was small and did not reach statistical significance, perhaps due
to the sodium-replete condition of our patients. The limited
follow-up of our study does not allow to address longer term
safety of NSAID therapy.
Our study has its limitations such as limited sample size and
study duration, and the post-hoc design. Given the heteroge-
neity of the population with respect to the underlying type of
renal disease, it may be surprising that significant reductions of
glomerular and proximal tubular biomarkers were found. This
suggests that irrespective of the underlying disease, one or more
shared pathophysiologic pathways (including proteinuria) are
reduced by NSAID treatment. The current findings cannot be
extrapolated to patients with more severe renal disease, who
may experience more side effects such as hyperkalemia or
edema, or patients on background RAAS blockade. The latter
category may not tolerate the combined regimen, and a
previous study has questioned the additional efficacy of NSAID
when give on top of maximum RAAS blockade as anti-
proteinuric therapy [31]. Furthermore it would be of interest to
study intra-individual changes of these biomarkers over time,
and their prognostic value, in a longitudinal analysis. Never-
theless our data may provide a rationale to prescribe NSAIDs
in patients with glomerular disease and proteinuria in whom
Table 3. Fractional excretion of damage markers in CKD
patients after a period with no anti-proteinuric treatment, and
after NSAID treatment.
Damage marker Untreated UP NSAID P
Total IgG (%) 6.6610
24
(0.9–14.3610
24)
3.0610
24
(0.7–8.0610
24)
0.03
IgG4 (%) 1.25 (0.62–3.89) 0.31 (0.14–0.50) 0.004
KIM-1 (%) 4.70 (3.53–8.56) 3.16 (1.32–6.02) 0.03
B2M (%) 0.83 (0.19–11.13) 0.30 (0.14–2.83) 0.04
H-FABP (%) 24.9 (9.9–150.5) 22.7 (2.9–164.0) 0.72
MCP-1 (%) 5.61 (4.25–8.31) 13.23 (6.80–22.47) 0.006
NGAL (%) 1.60 (1.04–4.01) 1.73 (0.65–4.64) 0.40
doi:10.1371/journal.pone.0037957.t003
Figure 2. Pre-treatment urinary MCP-1 excretion and treatment
response. Scatter plot indicating the relationship between the 24 h -
urinary excretion of MCP-1 before start of anti-proteinuric therapy (i.e.
NSAID) and the anti-proteinuric response (i.e. delta proteinuria without
vs with NSAID). A negative association is present, suggesting that high
baseline MCP-1 excretion is associated with poor anti-proteinuric
response to therapy.
doi:10.1371/journal.pone.0037957.g002
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ineffective or contra-indicated. Randomized controlled clinical
trials investigating the long-term renoprotective (i.e. protective
against loss of renal function) as well as cardiovascular effects of
NSAIDs (as monotherapy or on top of RAAS blockade) are,
however, warranted.
In conclusion, NSAID treatment is associated with a change
in urinary biomarker profile that suggests glomerulo- and
tubulo-protective effects along with reduction of proteinuria.
Our findings, although they cannot be extrapolated to a setting
of (maximally tolerated) background RAAS blockade with
optimal volume depletion, suggest that under specific conditions
NSAIDs may be used to reduce proteinuria as well as
glomerular and tubular damage markers in CKD. This may
be relevant given the prognostic importance of tubulointerstitial
damage for the progression of renal function loss [32,33]. On
the other hand no intra-renal anti-inflammatory effects of
NSAID treatment could be demonstrated and renal inflamma-
tion, another important prognostic determinant of renal function
loss [34], may even be increased by NSAID treatment. NSAID
may thus be considered with caution as a non-hypotensive
antiproteinuric therapy when RAAS blockade is not tolerated,
e.g. due to hypotension. Whether NSAIDs, either as mono-
therapy or given on top of RAAS blockade, have the potential
to modulate long term renal outcome remains to be proven.
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Table S1 Plasma levels of renal damage markers in CKD
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